AI-Enabled Pharmaceutical Cocrystal Screening

AI-Enabled Pharmaceutical Cocrystal Screening

Brought to you by Lonza

Overview

Optimizing the solid-state form of an active pharmaceutical ingredient (API) is critical to ensuring drug efficacy, stability, and manufacturability. Among available forms, cocrystals offer unique advantages for improving physicochemical properties, but identifying the best candidates is challenging due to the vast number of possible combinations.

This white paper explores how AI-driven modeling accelerates cocrystal screening, enabling data-driven decisions early in development and reducing costly late-stage surprises.

Key Objectives:

Why solid-form selection impacts bioavailability, safety, and IP protection.
Limitations of traditional cocrystal screening and associated risks.
Exploring how AI integration streamlines workflows and improves development outcomes.

Brought to you by:

Please complete the form to download the white paper.

Forwarded this link? Clear the form

Email Address*

Salutation

First Name*

Last Name*

Company*

Job Title

Address 1*

City*

State*

Zip / Post Code*

Country/Territory/Area*

Business Phone*

Are you facing challenges related to the solubility, stability, or manufacturability of your API that might benefit from solid form optimization?*

Would you be interested in leveraging AI-enabled tools (e.g., predictive cocrystal screening) accelerate your solid form selection and reduce trial-and-error experimentation?*

I would like to receive C&EN’s weekly newsletter with the latest in chemistry news

I would like to receive more information on products and services from the American Chemical Society

address2

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society and its sponsor via email. You understand that you can withdraw your consent at any time. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.